The United States Patent and Trademark Office (USPTO) has granted patent US12577322B2 to Amgen Inc. The patent covers diagnostic antibodies that bind to human and monkey mucin 17 (MUC17), along with a detection system utilizing these antibodies. These are intended for applications such as detecting or quantifying MUC17, diagnosing MUC17-associated diseases, stratifying patients, monitoring disease progression, and evaluating therapeutic responses.

This patent grant is primarily an intellectual property matter and does not impose direct regulatory obligations on companies. However, it may impact companies involved in MUC17 research, diagnostics, or therapeutics by establishing exclusive rights for Amgen Inc. in these specific antibody technologies. Companies operating in this space should be aware of this granted patent to ensure they do not infringe on the claimed intellectual property.